Innovations
Commented by Fabian Lorenz on November 7th, 2025 | 07:00 CET
Takeover battle between Novo Nordisk and Pfizer! Is BioNxt Solutions the next target?
Who will acquire Metsera? That is currently the subject of dispute between Novo Nordisk and Pfizer. Both pharma giants are seeking access to a new generation of metabolic therapies through the acquisition - treatments that have the potential to transform the billion-dollar market for obesity and diabetes care. Novo Nordisk views Metsera's drug pipeline as a complement to its GLP-1-based preparations, while Pfizer is trying to finally gain a foothold in the market after several setbacks. The takeover battle illustrates that big pharma companies are willing to dig deep into their pockets for innovations. This makes BioNxt Solutions a potential takeover candidate. The Company is not only working on innovations in the field of multiple sclerosis and obesity, but on an entire platform technology.
Read
Commented by André Will-Laudien on November 6th, 2025 | 07:10 CET
Novo Nordisk calculating carefully, Evotec facing potential takeover? Clinical trial and up-listing at Vidac!
The stock market is showing some turbulence in the biotech sector. Unlike the big growth stocks on the NASDAQ, there is still urgent catching-up to do here. Some figures, such as those from Novo Nordisk and Evotec, still give reason for concern. The situation is quite different at Vidac Pharma, where an up-listing to the primary market is on the horizon and a clinical trial is about to begin! Plenty of material for investors' dreams to grow. We calculate where an investment is worthwhile!
Read
Commented by Fabian Lorenz on November 5th, 2025 | 07:10 CET
Millions for BioNTech and Evotec! But drug development is costly! Is NetraMark the next takeover target?
NetraMark scores again. The Company's AI has convinced yet another biopharma company and is increasingly shaping up as a potential takeover target. The new client will use NetraAI to optimize its clinical trial, cutting both time and costs. The high expense of drug development is clear: BioNTech invested EUR 565 million into its pipeline last quarter. However, the German biotech leader can afford this thanks to billions in its coffers. Analysts still recommend buying the stock. By contrast, even a million-dollar payment from a partner could not give Evotec shares any real momentum. Could today’s figures finally spark a turnaround?
Read
Commented by Carsten Mainitz on November 4th, 2025 | 07:20 CET
Insider knowledge drives share prices: What does Almonty CEO Lewis Black have planned next? Insider purchases at TKMS and Aixtron are causing a stir!
The recent summit meeting between the heads of state of the United States and China ended with a preliminary trade agreement that promises a period of relative stability over the next twelve months. However, the agreements appear to be more symbolic than substantial, with few concrete steps to ease the structural tensions in global trade. One thing is clear: the US and Europe are under pressure to act. Without a decisive strategy to expand alternative production sites and relocate strategic supply chains to Western regions, there is a threat of a geopolitical and economic meltdown in the long term.
Read
Commented by Nico Popp on November 3rd, 2025 | 06:55 CET
Commodity-based investments without the boredom: Globex Mining, Royal Gold, Mercedes-Benz
The agreement in the trade dispute between the US and China is increasingly being seen for what it is – a temporary pause in escalation. The fact that negotiations are set to resume after a year and that China is only lifting the most recent trade restrictions shows that the era of globalization will not return. Going forward, China and the US will continue to monitor each other closely and try to secure the best deal for themselves. This carries the potential for further escalation. One collateral damage is already evident in the automotive industry. Here is why there are currently many arguments in favor of crisis-driven investments in the commodities sector.
Read
Commented by Armin Schulz on October 30th, 2025 | 07:15 CET
BioNxt Solutions: The underrated biotech gem you need to know - Potential partner for Merck and Novo Nordisk
Investing in biotech often feels like a rollercoaster ride. The sector regularly delivers groundbreaking success stories, yet just as often, promising studies come to nothing. For investors, this usually means a nerve-wracking journey with long dry spells and a true all-or-nothing gamble. But what if there was a way to avoid the typical risks without sacrificing the enormous upside potential? The Canadian company BioNxt Solutions is pursuing precisely this approach and could very well change the rules of the game in the biotech industry.
Read
Commented by Nico Popp on October 29th, 2025 | 07:30 CET
AI fantasy at biotech innovators: BioNxt, Roche, Merck & Co.
Biotechnology provides us with the medicines of tomorrow. But even with established active ingredients, innovation is possible. A prime example of this is the Canadian-German company BioNxt Solutions. This article outlines the strategy BioNxt is pursuing, which companies the emerging biotech startup could connect with, what new opportunities AI offers for its business model, and what this could mean for BioNxt shareholders.
Read
Commented by André Will-Laudien on October 24th, 2025 | 07:35 CEST
BioNxt Solutions advances sublingual MS therapy into decisive development phase
BioNxt Solutions is on the verge of a decisive step in the development of its novel sublingual cladribine formulation for the treatment of multiple sclerosis. Following successful small-animal studies, the Company is now launching a large-scale animal study to optimize dosage ahead of the planned human bioequivalence study in 2026. The orally soluble thin-film technology is designed to enable faster drug absorption, greater bioavailability, and easier administration. At the same time, BioNxt is securing patent protection in key global markets, further strengthening its position in the competitive field of advanced drug delivery systems. With its focus on patient-friendly, precise, and effective therapies, BioNxt could set a new standard in MS treatment. A promising setup for the coming months. What opportunities does the Company offer dynamic investors?
Read
Commented by Nico Popp on October 22nd, 2025 | 07:00 CEST
Important piece of the puzzle in the fight against cancer: Vidac Pharma, Roche, Merck & Co.
The pharmaceutical market is enormous - and continues to grow. Market research institute Evaluate forecasts an increase to around USD 1.7 trillion by 2030, representing an annual growth rate of 7.7%. Oncology promises the highest sales, at around USD 300 billion. However, there is no single approach. Instead, new modalities and technologies such as antibody-drug conjugates (ADCs), cell and gene therapies, and radiopharmaceuticals are transforming the industry and gaining significant traction. One thing is clear: progress in the biotech sector is increasingly achieved through the combination of active ingredients and technologies. What role does the biotech company Vidac Pharma play in this?
Read
Commented by Armin Schulz on October 20th, 2025 | 07:05 CEST
Why this structural change in medicine makes Novo Nordisk, PanGenomic Health, and Pfizer must-haves
The medicine of tomorrow does not think in terms of diseases but in terms of opportunities. A radical shift from repair to proactive prevention is revolutionizing the healthcare sector and opening up massive areas of growth. The focus is on personalized, data-driven solutions that improve quality of life and combat widespread diseases costing billions. This structural transformation is creating clear winners, led by pioneers who have mastered the new logic of the healthcare market. Three companies that embody this trend and make it tangible for investors are Novo Nordisk, PanGenomic Health, and Pfizer.
Read